Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844004 | 1.00 | DPP4 (0.46) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL809956 | 1.00 | DPP4 (0.46) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2840860 | 1.00 | DPP4 (0.46) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3856755 | 1.00 | DPP4 (0.46) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10193903 | 1.00 | DPP4 (0.46) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| Benzene SCHEMBL4865907 | 0.98 | DPP4 (0.45) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| Benzene SCHEMBL4859438 | 0.98 | DPP4 (0.45) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7091245 | 0.98 | DPP4 (0.45) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| Benzene SCHEMBL7089215 | 0.96 | DPP4 (0.43) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 | |
| Hexamethylbenzene SCHEMBL4856383 | 0.93 | DPP4 (0.41) | DPP4KEAP1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320221-A1 | NOVEL INTERMEDIATE, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF | UNIV SICHUAN (CN) | 2025-10-16 | — | — | US | disclosed |
| CN-119775208-A | Chiral bisimidazoline ligand containing cyclohexane skeleton structure and preparation method thereof | 北京化工大学 | 2025-04-08 | — | — | CN | disclosed |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4201926-A1 | NOVEL INTERMEDIATE, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | Sichuan University (CN) | 2023-06-28 | — | — | EP | disclosed |
| EP-4115975-A1 | CATALYST CONTAINING ACTIVATED CARBON ON WHICH RUTHENIUM COMPLEX IS ADSORBED, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | Takasago International Corporation (JP) | 2023-01-11 | — | — | EP | disclosed |
| CN-110099893-B | Preparation method of droxidopa and intermediate thereof | 广东东阳光药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| EP-3205656-A1 | SOLID-SUPPORTED RUTHENIUM-DIAMINE COMPLEX, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | Takasago International Corporation (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-9468919-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2016-03-10 | — | — | US | disclosed |
| US-9217005-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-12-22 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| EP-1439159-B1 | Process for producing optically active compound | KANTO KAGAKU (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060069098-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1308435-B1 | Process for producing optically active amino alcohols | KANTO KAGAKU (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1439159-A1 | Process for producing optically active compound | Kanto Kagaku Kabushiki Kaisha (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1308435-A2 | Process for producing optically active amino alcohols | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | DPP4 2468/4885KEAP1 2454/4885CYP1A2 138/4885 |
| US-20060069098-A1 | Bicyclic compound | CRH, NR3C2, CRHR1 | DPP4 2210/4885KEAP1 2211/4885CYP1A2 1522/4885 |
| US-20250320221-A1 | NOVEL INTERMEDIATE, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF | OPRK1, OPRM1, OPRD1 | DPP4 1617/4885KEAP1 270/4885CYP1A2 9/4885 |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | RRS1, POR, SCO2 | DPP4 4838/4885KEAP1 1509/4885CYP1A2 41/4885 |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH1A, ADH1C, ADH5 | DPP4 4525/4885KEAP1 2131/4885CYP1A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.